Mitotane has a strong and a durable inducing effect on CYP3A4 activity

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Faivre, S. J., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C. L., DePrimo, S. E., Brega, N. M., Massimini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,162 · see citing works

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Goodman, V. L., Rock, E. P., Dagher, R. N., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 502 · see citing works

Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

Kirn, R. B., Wandel, C., Leake, B. F., Cvetković, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F. J., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454 · see citing works

Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach

Fuhr, U., Jetter, A., & Kirchheiner, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100050 · Cited by 246 · see citing works

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

Houk, B. E., Bello, C. L., Kang, D., & Amantea, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1893 · Cited by 232 · see citing works

Management of adrenocortical carcinoma

Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214 · see citing works

Mitotane for adrenocortical carcinoma treatment.

Hahner, S., & Faßnacht, M. (2005) · PubMed · Cited by 153 · see citing works

Comparison of midazolam and simvastatin as cytochrome P450 3A probes

CHUNG, E., Nafziger, A. N., Kazierad, D. J., & BERTINOJR, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.016 · Cited by 111 · see citing works

Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

Magnusson, M. O., Dahl, M.-L., Cederberg, J., Karlsson, M., & Sandström, R. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100431 · Cited by 92 · see citing works

Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450‐3A Activity: Comparison With Grapefruit Juice

Farkas, D., Oleson, L. E., Zhao, Y., Harmatz, J. S., Zinny, M. A., Court, M. H., & Greenblatt, D. J. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298359 · Cited by 89 · see citing works

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity

Kurnik, D., Wood, A., & Wilkinson, G. R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.002 · Cited by 75 · see citing works

Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆

Minkin, P., Zhao, M., CHEN, Z., OUWERKERK, J., Gelderblom, H. A. J., & Baker, S. D. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.09.007 · Cited by 69 · see citing works

No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers

Mueller, S., Majcher-Peszynska, J., Mundkowski, R. G., Uehleke, B., Klammt, S., Sievers, H., Lehnfeld, R., Frank, B., Thurow, K., Kundt, G., et al. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0554-y · Cited by 60 · see citing works

Metabolic Activation and Binding of Mitotane in Adrenal Cortex Homogenates

Cai, W., Counsell, R. E., Djanegara, T., SCHTEINGART, D. E., Sinsheimer, J. E., & Wotring, L. L. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840203 · Cited by 56 · see citing works

Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria

Martz, F., & Straw, J. A. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00240-5 · Cited by 55 · see citing works

Marginal increase of sunitinib exposure by grapefruit juice

van Erp, N. P., Baker, S. D., Zandvliet, A. S., Ploeger, B. A., den Hollander, M., Chen, Z., den Hartigh, J., König-Quartel, J. M. C., Guchelaar, H., & Gelderblom, H. A. J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1367-0 · Cited by 52 · see citing works

ORGANOCHLORINE INSECTICIDES AND THE STIMULATION OF LIVER MICROSOME ENZYMES*

Street, J. C. (1969) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1969.tb15848.x · Cited by 49 · see citing works

HEPATIC MICROSOMAL ENZYME INDUCTION AND ADRENAL CRISIS DUE TO o,p’DDD THERAPY FOR METASTATIC ADRENOCORTICAL CARCINOMA

Hague, R. V., MAY, W., & Cullen, D. R. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00453.x · Cited by 49 · see citing works

Possible Mechanism and Treatment of o,p' DDD-induced Hypercholesterolaemia

MAHER, V., Trainer, P. J., Scoppola, A., Anderson, J. V., Thompson, G., & BESSER, G. M. (1992) · QJM · doi:10.1093/oxfordjournals.qjmed.a068705 · Cited by 48 · see citing works

Regression of Adrenal Cancer and Suppression of Adrenal Function in Man by o,p′-DDD

Bergenstal, D. M., LIPSETT, M. B., MOY, R. H., & Hertz, R. (1960) · Elsevier eBooks · doi:10.1016/b978-1-4832-2866-2.50035-0 · Cited by 48 · see citing works

Prolonged bleeding time due to mitotane therapy

Haak, H. R., Caekebeke‐Peerlinck, K. M. J., van Seters, A. P., & Briët, E. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90233-4 · Cited by 28 · see citing works

Adrenal proteins bound by a reactive intermediate of mitotane

Cai, W., Counsell, R. E., Schteingart, D. E., Sinsheimer, J. E., Vaz, A. D. N., & Wotring, L. L. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050610 · Cited by 27 · see citing works

Estimation of o,p'-DDD in plasma by gas-liquid chromatography

Moolenaar, A. J., Niewint, J. W. M., & Oei, I. T. (1977) · Clinica Chimica Acta · doi:10.1016/0009-8981(77)90098-5 · Cited by 24 · see citing works

Influence of Mitotane on the Hypoprothrombinemic Effect of Warfarin

Cuddy, P. G., & Loftus, L. (1986) · Southern Medical Journal · doi:10.1097/00007611-198603000-00037 · Cited by 17 · see citing works

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works

Adrenocortical carcinoma

Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874 · see citing works

The Treatment of Cushing's Disease

Pivonello, R., Leo, M. D., Cozzolino, A., & Colao, A. A. L. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 471 · see citing works

Inhibition and induction of CYP enzymes in humans: an update

Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 422 · see citing works

Update in Adrenocortical Carcinoma

Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414 · see citing works

Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Berruti, A., Baudin, É., Gelderblom, H. A. J., Haak, H. R., Porpiglia, F., Faßnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 330 · see citing works

Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial

Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175 · see citing works

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement

Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154 · see citing works

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma: CYP3A4 induction by mitotane

Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148 · see citing works

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials

Pivonello, R., Ferrigno, R., Martino, M. C. D., Simeoli, C., Paola, N. D., Pivonello, C., Barba, L., Negri, M., de Angelis, C., & Colao, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00648 · Cited by 130 · see citing works

Drug interactions with solid tumour-targeted therapies

Thomas‐Schoemann, A., Blanchet, B., Bardin, C., Noé, G., Boudou, P., Vidal, M., & Goldwasser, F. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.007 · Cited by 112 · see citing works

Next-generation therapies for adrenocortical carcinoma

Altieri, B., Ronchi, C. L., Kroiß, M., & Faßnacht, M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101434 · Cited by 100 · see citing works

Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells

Hescot, S., Slama, A., Lombès, A., Paci, A., Remy, H., Leboulleux, S., Chadarévian, R., Trabado, S., Amazit, L., Young, J., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0368 · Cited by 98 · see citing works

Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma

Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Mueller, H. H., Skogseid, B. M., Leboulleux, S., Mantero, F., Haak, H. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2281 · Cited by 94 · see citing works

Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies

Fleseriu, M., & Castinetti, F. (2016) · Pituitary · doi:10.1007/s11102-016-0742-1 · Cited by 87 · see citing works

The role of pregnane X receptor (PXR) in substance metabolism

Lv, Y., Luo, Y., Ren, H., Li, C., Xiang, Z.-X., & Luan, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.959902 · Cited by 85 · see citing works

Induction of cytochrome P450 enzymes: a view on human in vivo findings

Hukkanen, J. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.39 · Cited by 73 · see citing works

Adrenocortical Carcinoma

Baudin, É. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.03.001 · Cited by 66 · see citing works

Pharmacological profile and effects of mitotane in adrenocortical carcinoma

Corso, C. R., Acco, A., Bach, C., Bonatto, S. J. R., de Figueiredo, B. C., & de Souza, L. M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14721 · Cited by 67 · see citing works

Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib

Kroiß, M., Megerle, F., Kurlbaum, M., Zimmermann, S., Wendler, J., Jiménez, C., Lapa, C., Quinkler, M. O., Scherf‐Clavel, O., Habra, M. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz318 · Cited by 64 · see citing works

Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Casa, S. D., Loli, P., Luconi, M., Mantero, F., & Terzolo, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0349-9 · Cited by 61 · see citing works

Future directions in the diagnosis and medical treatment of adrenocortical carcinoma

Creemers, S. G., Hofland, L. J., Korpershoek, E., Franssen, G. J. H., van Kemenade, F. J., de Herder, W. W., & Feelders, R. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0452 · Cited by 59 · see citing works

Diagnosis, treatment and outcome of adrenocortical cancer

Mihai, R. (2015) · British journal of surgery · doi:10.1002/bjs.9743 · Cited by 56 · see citing works

Everolimus therapy for progressive adrenocortical cancer

Fraenkel, M., Gueorguiev, M., Barak, D. F., Salmon, A. Y., Grossman, A. B., & Gross, D. J. (2013) · Endocrine · doi:10.1007/s12020-013-9878-1 · Cited by 53 · see citing works

Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide

Varlamov, E. V., Han, A. J., & Fleseriu, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101490 · Cited by 55 · see citing works

Medical Management of Cushing’s Syndrome: Current and Emerging Treatments

Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 53 · see citing works

Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?

Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 51 · see citing works

Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

Shao, J., Markowitz, J. S., Bei, D., & An, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24113 · Cited by 46 · see citing works

Update on medical treatment for Cushing’s disease

Cuevas-Ramos, D., Lim, D., & Fleseriu, M. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0033-9 · Cited by 40 · see citing works

Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane

D’Avolio, A., Francia, S. D., Basile, V., Cusato, J., Martino, F., Pirro, E., Piccione, F. M., Ardito, A., Zaggia, B., Volante, M., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283606cb2 · Cited by 42 · see citing works

Developing treatment for adrenocortical carcinoma

Kerkhofs, T. M. A., Ettaieb, M. H. T., Hermsen, I. G. C., & Haak, H. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0318 · Cited by 41 · see citing works

Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia

Karpale, M., Hukkanen, J., & Hakkola, J. (2022) · Cells · doi:10.3390/cells11030313 · Cited by 40 · see citing works

EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?

Ronchi, C. L., Kroiß, M., Sbiera, S., Deutschbein, T., & Faßnacht, M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0273 · Cited by 39 · see citing works

Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches

Hall, A., Chanteux, H., Ménochet, K., Ledecq, M., & Schulze, M. E. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02245 · Cited by 38 · see citing works

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults

Armani, S., Ting, L. S. L., Sauter, N. P., Darstein, C., Tripathi, A. P., Wang, L., Zhu, B. Y., Gu, H., Chun, D. Y., Einolf, H. J., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0497-0 · Cited by 37 · see citing works

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies

Bolleddula, J., Gopalakrishnan, S., Hu, P., Dong, J. Q., & Venkatakrishnan, K. (2022) · Clinical and Translational Science · doi:10.1111/cts.13357 · Cited by 35 · see citing works

Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells

Lin, C.-W., Chang, Y., & Pu, H. (2012) · Toxicology · doi:10.1016/j.tox.2012.04.007 · Cited by 34 · see citing works

Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies

Lerário, A. M., Mohan, D. R., & Hammer, G. D. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac012 · Cited by 34 · see citing works

Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro

Theile, D., Haefeli, W. E., & Weiß, J. (2014) · Endocrine · doi:10.1007/s12020-014-0517-2 · Cited by 33 · see citing works

Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial

Campbell, M. T., Balderrama-Brondani, V., Jiménez, C., Tamsen, G., Marcal, L. P., Varghese, J. M., Shah, A. Y., Long, J. P., Zhang, M., Ochieng, J. K., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00095-0 · Cited by 31 · see citing works

Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas

Subramanian, C., Kuai, R., Zhu, Q., White, P., Moon, J. J., Schwendeman, A. A., & Cohen, M. S. (2015) · Surgery · doi:10.1016/j.surg.2015.08.023 · Cited by 31 · see citing works

Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery

Capatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 30 · see citing works

The next generation of therapies for adrenocortical cancers

Kirschner, L. S. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.001 · Cited by 27 · see citing works

ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo

Cheng, Y., Kerppola, R. E., & Kerppola, T. K. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0527 · Cited by 27 · see citing works

Effects of mitotane treatment on human steroid metabolism: implications for patient management

Ghataore, L., Chakraborti, I., Aylwin, S. J. B., Schulte, K., Dorota Dworakowska, B., Coskeran, P., & Taylor, N. (2012) · Endocrine Connections · doi:10.1530/ec-12-0028 · Cited by 26 · see citing works

Population Pharmacokinetic Model Characterizing 24‐Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers

van Rongen, A., Kervezee, L., Brill, M. J. E., van Meir, H., den Hartigh, J., Guchelaar, H., Meijer, J. H., Burggraaf, J., & van Oosterhout, F. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12007 · Cited by 26 · see citing works

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

de Wit, D., Gelderblom, H. A. J., Sparreboom, A., den Hartigh, J., den Hollander, M., König-Quartel, J. M. C., Hessing, T. J., Guchelaar, H., & van Erp, N. P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2322-7 · Cited by 26 · see citing works

A review of mitotane in the management of adrenocortical cancer

Rivero, J. D., Else, T., Johnson, J. E. H., Kiseljak‐Vassiliades, K., Raj, N. P., Reidy‐Lagunes, D. L., Srinivas, S., Gilbert, J., Vaidya, A., Aboujaoude, E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae084 · Cited by 24 · see citing works

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging

Haider, M. S., Ahmad, T., Gröll, J., Scherf‐Clavel, O., Kroiß, M., & Luxenhofer, R. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00700-5 · Cited by 26 · see citing works

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma

Miller, K. C., Chintakuntlawar, A. V., Hilger, C. R., Bancos, I., Morris, J. C., Ryder, M. M., Smith, C. Y., Jenkins, S. M., & Bible, K. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa069 · Cited by 24 · see citing works

Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry

Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Hescot, S., Körbl, D., Megerle, F., Beuschlein, F., Neu, B., Quinkler, M. O., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0747-5571 · Cited by 23 · see citing works

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?

Cazaubon, Y., Talineau, Y., Féliu, C., Konecki, C., Russello, J., Mathieu, O., & Djerada, Z. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110566 · Cited by 23 · see citing works

Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma

Kroiß, M., Plonné, D., Kendl, S., Schirmer, D., Ronchi, C. L., Schirbel, A., Zink, M., Lapa, C., Klinker, H., Faßnacht, M., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0946 · Cited by 23 · see citing works

Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide

on behalf of the German Adrenocortical Carcinoma Study Group, Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Neu, B., Müller, H., Quinkler, M. O., Hahner, S., Heidemeier, A., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0260-7 · Cited by 22 · see citing works

A Micellar Mitotane Formulation with High Drug‐Loading and Solubility: Physico‐Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models

Haider, M. S., Schreiner, J., Kendl, S., Kroiß, M., & Luxenhofer, R. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900178 · Cited by 21 · see citing works

Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19 · see citing works

Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor

Takeshita, A., Igarashi-Migitaka, J., Koibuchi, N., & Takeuchi, Y. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0297 · Cited by 21 · see citing works

New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma

Stigliano, A., Cerquetti, L., Lardo, P., Petrangeli, E., & Toscano, V. (2017) · Oncology Reports · doi:10.3892/or.2017.5427 · Cited by 20 · see citing works

Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use

Gougis, P., Palmieri, L., Funck‐Brentano, C., Paci, A., Flippot, R., Mir, O., & Coriat, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.006 · Cited by 20 · see citing works

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects

Hart, X. M., Gründer, G., Unterecker, S., Schoretsanitis, G., Hiemke, C., Adamovic, I., Amann, F., Baumann, P., Bergemann, N., Brandt, C., et al. (2026) · Pharmacopsychiatry · doi:10.1055/a-2860-7861 · Cited by 20 · see citing works

Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells

Kroiß, M., Sbiera, S., Kendl, S., Kurlbaum, M., & Faßnacht, M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0273-2 · Cited by 19 · see citing works

Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients

Arshad, U., Taubert, M., Kurlbaum, M., Frechen, S., Herterich, S., Megerle, F., Hamacher, S., Faßnacht, M., Fuhr, U., & Kroiß, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0342 · Cited by 19 · see citing works

Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma

Germano, A., Rapa, I., Duregon, E., Votta, A., Giorcelli, J., Buttigliero, C., Scagliotti, G. V., Volante, M., Terzolo, M., & Papotti, M. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9473-8 · Cited by 17 · see citing works

Xenograft models for preclinical drug testing: Implications for adrenocortical cancer

Luconi, M., & Mannelli, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.043 · Cited by 17 · see citing works

Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers

Breithaupt, M. H., Krohmer, E., Taylor, L. A., Koerner, E., Hoppe‐Tichy, T., Burhenne, J., Foerster, K. I., Dachtler, M., Huber, G., Venkatesh, R., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15720 · Cited by 15 · see citing works

Current approaches to the pharmacological management of Cushing's disease

Molitch, M. E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.021 · Cited by 15 · see citing works

The role of mTOR pathway as target for treatment in adrenocortical cancer

Martino, M. C. D., Feelders, R. A., Pivonello, C., Simeoli, C., Papa, F., Colao, A., Pivonello, R., & Hofland, L. J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0224 · Cited by 14 · see citing works

Phenotyping drug disposition in oncology

Opdam, F. L., Gelderblom, H. A. J., & Guchelaar, H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.003 · Cited by 12 · see citing works

Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells

Abate, A., Rossini, E., Tamburello, M., Laganà, M., Cosentini, D., Grisanti, S., Fiorentini, C., Tiberio, G. A. M., Scatolini, M., Grosso, E., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab248 · Cited by 13 · see citing works

Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options

Hescheler, D. A., Hartmann, M. J. M., Riemann, B., Michel, M., Bruns, C. J., Alakus, H., & Chiapponi, C. (2022) · Cancers · doi:10.3390/cancers14112721 · Cited by 10 · see citing works

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study

Jouinot, A., Royer, B., Chatelut, É., Moeung, S., Assié, G., Thomas‐Schoemann, A., Bertherat, J. Y., Goldwasser, F., & Blanchet, B. (2018) · Endocrine Connections · doi:10.1530/ec-18-0428 · Cited by 9 · see citing works

Medical Treatment of Cushing’s Disease

Hopkins, S., & Fleseriu, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00007-3 · Cited by 8 · see citing works

Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma

Zhuang, J., Wang, D., Wu, R., Tu, X.-A., Chen, Y., & Qiu, S. (2015) · International Journal of Urology · doi:10.1111/iju.12903 · Cited by 8 · see citing works

Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3

Keminer, O., Windshügel, B., Eßmann, F., Lee, S. M. L., Schiergens, T. S., Schwab, M. G., & Burk, O. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02495-6 · Cited by 7 · see citing works

Immediate versus modified release hydrocortisone in mitotane‐treated patients with adrenocortical cancer

Weigel, M., Hahner, S., Sherlock, M., Agha, A., Behan, L., Stewart, P. M., Arlt, W., Beier, D., Frey, K. R., Zopf, K., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13302 · Cited by 7 · see citing works

Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?

Ronchi, C. L., Kroiß, M., Sbiera, S., Deutschbein, T., & Faßnacht, M. (2014) · Cited by 6 · see citing works

Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma – case series and literature review

Moszczyńska, E., Baszyńska–Wilk, M., Tutka, A., Bogusz-Wójcik, A., Dasiewicz, P., Gryniewicz–Kwiatkowska, O., Walewska‐Wolf, M., Stepaniuk, M., Majak, D., & Grajkowska, W. (2024) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.133315 · Cited by 6 · see citing works

Mécanismes des interactions pharmacocinétiques impliquant les agents anticancéreux oraux

Levêque, D., Duval, C., Poulat, C., Palas, B., Aatmani, A. E., Dory, A., Becker, G., & Gourieux, B. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2014.11.001 · Cited by 6 · see citing works

Oral anticancer agents as generators of relevant pharmacokinetic interactions

Machkouri, C., & Levêque, D. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.04.016 · Cited by 5 · see citing works

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

Zhang, J., Wu, L., Su, T., Liu, H., Jiang, L., Jiang, Y., Wu, Z., Chen, L., Li, H., Zheng, J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1365321 · Cited by 5 · see citing works

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Wang, L., Lyu, Y., Li, Y., Li, K., Wen, H., Feng, C., & Li, N. (2021) · Aging · doi:10.18632/aging.203534 · Cited by 4 · see citing works

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma

Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Leboulleux, S., Mantero, F., Haak, H. R., & Faßnacht, M. (2013) · Endocrine Abstracts · doi:10.1530/endoabs.32.p516 · Cited by 4 · see citing works

The Efficacy and Safety of Multi-Kinase Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Single-Arm Meta-Analysis

Flauto, F., & Damiano, V. (2025) · Cancers · doi:10.3390/cancers17122004 · Cited by 3 · see citing works

Emerging drugs for the treatment of adrenocortical carcinoma

Sukrithan, V., Husain, M., Kirschner, L. S., Shah, M. H., & Konda, B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1920922 · Cited by 3 · see citing works

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri, B., Kimpel, O., Megerle, F., Detomas, M., Chifu, I. O., Fuß, C. T., Quinkler, M. O., Kroiß, M., & Faßnacht, M. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae007 · Cited by 3 · see citing works

Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Puszkiel, A., Noé, G., Thomas‐Schoemann, A., Bellesœur, A., Boudou, P., Vidal, M., Goldwasser, F., & Blanchet, B. (2017) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2017-0008 · Cited by 3 · see citing works

A Fly in the Ointment: Reassessing Mitotane‘s Role in the Treatment of Adrenocortical Carcinoma

Bapat, A., Demeure, M. J., & Bussey, K. J. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.90 · Cited by 3 · see citing works

Adrenocortical carcinoma

Ettaieb, M. H. T. (2020) · doi:10.26481/dis.20201218me · Cited by 4 · see citing works

The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma

Liu, X., Shang, J., Fu, Q., Lü, L., Deng, J., Tang, Y., Li, J., Mei, D., Zhang, B., & Zhang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919027 · Cited by 2 · see citing works

Arzneimitteltherapiesicherheit: Pharmakokinetik von Onkologika

Petri, H. (2017) · Deutsches Ärzteblatt · doi:10.3238/personko/2017.02.03.07 · Cited by 2 · see citing works

Mitotane in adrenocortical carcinoma: a profile of its use

Shirley, M. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00958-y · Cited by 2 · see citing works

Induction of Cytochrome P450 Systems

Coleman, M. D. (2010) · doi:10.1002/9780470689332.ch4 · Cited by 2 · see citing works

Medical management of Cushing's disease

Kelsall, A., & Newell-Price, J. D. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00046-9 · Cited by 2 · see citing works

Сurrent options and perspectives of systemic therapy for advanced or metastatic adrenocortical cancer

Zhulikov, Y. А., Kovalenko, E. I., Bokhian, V., & Артамонова, Е. В. (2022) · Malignant tumours · doi:10.18027/2224-5057-2021-11-3-36-44 · Cited by 1 · see citing works

Immune-Mediated Liver Injury From Checkpoint Inhibitors Requiring Supratherapeutic Corticosteroid and Mycophenolate Treatment

Pham, C. H., Ennin, E., Enriquez, K. T., Wong, A., Cannon, S. M., Dukewich, M., LoPresti, J. S., Dara, L., & Torres, E. T. R. (2024) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.0779 · Cited by 1 · see citing works

Diagnosis and Management of Adrenocortical Carcinoma

Balderrama-Brondani, V., & Habra, M. A. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.01.006 · Cited by 1 · see citing works

Corticosurrénalomes: actualités thérapeutiques

Grunenwald, S., & Caron, P. (2011) · Annales d Endocrinologie · doi:10.1016/s0003-4266(11)70004-x · Cited by 1 · see citing works

Thérapies ciblées en oncologie endocrinienne : facteurs pronostiques et prédictifs de réponse

Hescot, S., Baudin, É., Borson‐Chazot, F., & Lombès, M. (2013) · Annales d Endocrinologie · doi:10.1016/s0003-4266(13)70017-9 · Cited by 1 · see citing works

ATHENA Research Book,Volume 1

Györkös, J., Blonder, R., Delouis, A. F., Javornik, J., & Petridis, K. (2022) · University of Maribor, University Press eBooks · doi:10.18690/um.3.2022 · Cited by 1 · see citing works

Composer-Computer-Interpreter. A Three-way Collaborative Process to the Creation of Two New Works for Multipercussion

Andrikopoulos, D., Aroso, N., & ESMAE/IPP-CESEM, R. D. A. 5. (2022) · University of Maribor, University Press eBooks · doi:10.18690/um.3.2022.1 · Cited by 1 · see citing works

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma: CYP3A4 induction by mitotane

Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148 · see citing works

Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor

Takeshita, A., Igarashi-Migitaka, J., Koibuchi, N., & Takeuchi, Y. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0297 · Cited by 21 · see citing works

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

de Wit, D., Gelderblom, H. A. J., Sparreboom, A., den Hartigh, J., den Hollander, M., König-Quartel, J. M. C., Hessing, T. J., Guchelaar, H., & van Erp, N. P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2322-7 · Cited by 26 · see citing works

CYP3A4 phenotyping with midazolam to predict sunitinib exposure.

van Erp, N. P., de Wit, D., Sparreboom, A., den Hartigh, J., den Hollander, M., König-Quartel, J. M. C., Hessing, T. J., Guchelaar, H., & Gelderblom, H. A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2592 · Cited by 1 · see citing works

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation

Sugiyama, M., Fujita, K., Murayama, N., Akiyama, Y., Yamazaki, H., & Sasaki, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037853 · Cited by 52 · see citing works